Literature DB >> 29113181

MicroRNA profiling and bioinformatics analyses reveal the potential roles of microRNAs in chordoma.

Kangwu Chen1, Hao Chen1, Kai Zhang1, Siwei Sun1, Jianqiang Mo1, Jian Lu1, Zhonglai Qian1, Huilin Yang1.   

Abstract

Chordoma is a rare aggressive bone tumor arising from remnants of the notochord, and patients with chordoma have a poor prognosis. However, the unique expression profiles of microRNAs (miRNAs/miRs) and their downstream signaling pathways in chordoma remain incompletely characterized. The aim of the present study was to delineate the global miRNA expression profile and associated signaling networks in chordoma. miRNA profiling was performed on chordoma and fetal notochord tissues. Differentially expressed miRNAs in chordoma were analyzed using microarrays with hierarchical clustering analysis. The target genes of the differentially expressed miRNAs were predicted, and Gene Ontology (GO) and pathway analyses were performed for the intersecting genes. A total of 42 miRNAs were significantly dysregulated in chordoma compared with that in fetal nucleus pulposus tissues. The expression of hsa-miR-21-3p, hsa-miR-150-5p, hsa-miR-1290 and hsa-miR-623 were validated using the reverse transcription-quantitative polymerase chain reaction. On the basis of the intersection predicted by three databases (Targetscan, microRNA.org and PITA), 10,292 potential miRNA targets were identified. Bioinformatic analyses suggested that these dysregulated miRNAs and their predicted targets were functions of signaling pathways in cancer, the mitogen-activated protein kinase signaling pathway, regulation of actin cytoskeleton, focal adhesion and endocytosis. In particular, human (hsa-)miR-185-5p was identified as a crucial miRNA in chordoma development via the Wnt signaling pathway. The results of the present study provide a comprehensive expression and functional profile of differentially expressed miRNAs associated with chordoma. This profile may serve as a potential tool for biomarker and therapeutic target identification in patients with chordoma.

Entities:  

Keywords:  bioinformatics analyses; chordoma; microRNA; microarray; nucleus pulposus

Year:  2017        PMID: 29113181      PMCID: PMC5654481          DOI: 10.3892/ol.2017.6839

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  24 in total

1.  Chordoma: incidence and survival patterns in the United States, 1973-1995.

Authors:  M L McMaster; A M Goldstein; C M Bromley; N Ishibe; D M Parry
Journal:  Cancer Causes Control       Date:  2001-01       Impact factor: 2.506

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  Operative management of sacral chordoma.

Authors:  Bruno Fuchs; Ian D Dickey; Michael J Yaszemski; Carrie Y Inwards; Franklin H Sim
Journal:  J Bone Joint Surg Am       Date:  2005-10       Impact factor: 5.284

Review 4.  Wnt/β-catenin pathway in bone cancers.

Authors:  Jian Tian; Hongbo He; Guanghua Lei
Journal:  Tumour Biol       Date:  2014-08-13

5.  Overexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence.

Authors:  Kai Zhang; Hao Chen; Bin Zhang; Jiajia Sun; Jian Lu; Kangwu Chen; Huilin Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

6.  Histological study of chordoma origin from fetal notochordal cell rests.

Authors:  Jun Shen; Qin Shi; Jian Lu; Dong-Lai Wang; Tian-Ming Zou; Hui-Lin Yang; Guo-Qing Zhu
Journal:  Spine (Phila Pa 1976)       Date:  2013-12-01       Impact factor: 3.468

Review 7.  Chordoma: the nonsarcoma primary bone tumor.

Authors:  Rashmi Chugh; Hussein Tawbi; David R Lucas; J Sybil Biermann; Scott M Schuetze; Laurence H Baker
Journal:  Oncologist       Date:  2007-11

Review 8.  Chordoma.

Authors:  Paolo G Casali; Silvia Stacchiotti; Claudia Sangalli; Patrizia Olmi; Alessandro Gronchi
Journal:  Curr Opin Oncol       Date:  2007-07       Impact factor: 3.645

9.  Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas.

Authors:  Elena Tamborini; Emanuela Virdis; Tiziana Negri; Marta Orsenigo; Silvia Brich; Elena Conca; Alessandro Gronchi; Silvia Stacchiotti; Giacomo Manenti; Paolo G Casali; Marco A Pierotti; Silvana Pilotti
Journal:  Neuro Oncol       Date:  2010-02-17       Impact factor: 12.300

10.  miR-185-3p regulates nasopharyngeal carcinoma radioresistance by targeting WNT2B in vitro.

Authors:  Guo Li; Yunyun Wang; Yong Liu; Zhongwu Su; Chao Liu; Shuling Ren; Tengbo Deng; Donghai Huang; Yongquan Tian; Yuanzheng Qiu
Journal:  Cancer Sci       Date:  2014-11-20       Impact factor: 6.716

View more
  3 in total

1.  A giant lumbar chordoma: A case report.

Authors:  Yibiao Zhou; Bolin Hu; Zhiwei Wu; Hanxiong Cheng; Min Dai; Bin Zhang
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

2.  LncRNA-NONHSAT024778 promote the proliferation and invasion of chordoma cell by regulating miR-1290/Robo1 axis.

Authors:  Bin Wang; Kai Zhang; Sen Meng; Xiaofeng Shao; Zhangzhe Zhou; Haiqing Mao; Ziqiang Zhu; Hao Chen; Huilin Yang; Kangwu Chen
Journal:  Int J Biol Sci       Date:  2021-02-08       Impact factor: 6.580

3.  miR-1290 inhibits chordoma cell proliferation and invasion by targeting Robo1.

Authors:  Bin Wang; Kai Zhang; Hao Chen; Jian Lu; Guizhong Wu; Huilin Yang; Kangwu Chen
Journal:  Transl Cancer Res       Date:  2019-04       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.